Ah, skepticism, how I love thee.

We rebel investors at Motley Fool Rule Breakers believe that multibaggers in the making, while not often cheap by the numbers, are always misunderstood. As such, they face extraordinary skepticism, which makes them excellent value stocks.

More are out there. Each week, right here in this column, we'll hunt them down. Grab your keyboard.

What one stock can do for you
Really, it's worth your time. One home run stock can make all the difference to your portfolio.

Just ask David Gardner, captain of the good pirate ship Rule Breakers. He bought Amazon at a split-adjusted price of $3.24 a share in 1997. He's up more than 2,000% since.

That helped him to overcome stinging losses from Celera (NYSE:CRA), Sirius Satellite Radio, and others to put up nine years of better-than-20% average annual returns as the leader of the real-money Rule Breaker portfolio.

Let the haters be your friends
Today, David and his team still seek misunderstood growers. You can, too, with the help of our completely free-of-charge Motley Fool CAPS investor-intelligence database, which currently contains information on more than 4,700 stocks.

CAPS applies user input to rate stocks from one star (low) to five (high). Using CAPS, we'll once again search for one- and two-star stocks that have at least 5% of their available shares sold short, but are expected to grow their earnings by no less than 15% over each of the next five years.

Let's have the list
Here are our latest five unloved growth stocks:


CAPS Rating

Short Interest

5-Year Growth Estimate









InnerWorkings (NASDAQ:INWK)




Under Armour (NYSE:UA)




Champion Enterprises (NYSE:CHB)




Sources: Motley Fool CAPS, Yahoo! Finance.

Bear in mind that this isn't a list of recommendations. Instead, I offer these stocks as candidates for further research. But of these five, medical device maker ev3 interests me most. I'll let CAPS All-Star DiscoJohn explain the thesis:

This company has seen solid growth in all quarters for almost the entirety of their existence, and there's no reason for it to stop now. In the last 3 years, they've released more products than any other peripheral vascular disease company.

They've established their dominance on the market share, and that share is only going to increase as baby boomers age and minimally invasive procedures become more popular.

Intrigued? Do your own due diligence, then check in with thousands of other investors at CAPS. And, if you'd like, add your own commentary. You'll be helping your fellow Fools and testing your ideas at the same time. Click here to get started now. The service is 100% free.

See you back here next week for five more unloved growth stocks.

How great is growth? Ten of the dozens of stocks in the market-beating Motley Fool Rule Breakers portfolio have more than doubled. Discover their identities with a free 30-day trial subscription.

Amazon is a Stock Advisor pick. Under Armour is a Rule Breakers recommendation.

Fool contributor Tim Beyers, ranked 2,478 out of more than 60,000 participants in CAPS, is part of the Rule Breakers team. Tim didn't own shares in any of the companies mentioned in this article at the time of publication. Click here for Tim's portfolio and here for his latest blog commentary. The Motley Fool's disclosure policy is your portfolio's competitive advantage.